Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the department of defense prostate cancer clinical trials consortium

Cancer

Volumn 117, Issue 11, 2011, Pages 2419-2425

  Harzstark, Andrea L ^a   Rosenberg, Jonathan E ^b   Weinberg, Vivian K ^a   Sharib, Jeremy ^a   Ryan, Charles J ^a   Smith, David C ^c   Pagliaro, Lance C ^d   Beer, Tomasz M ^e   Liu, Glenn ^f   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Chemotherapy; Docetaxel; Ixabepilone; Metastatic; Mitoxantrone; Prostate cancer

Indexed keywords

ANTIBODY; BICALUTAMIDE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL ARTHRITIS; BLOODSTREAM INFECTION; CANCER GROWTH; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CELLULITIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN INFECTION; SYNCOPE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UROSEPSIS;

CHEMOTHERAPY; DOCETAXEL; IXABEPILONE; METASTATIC; MITOXANTRONE; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPOTHILONES; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 79953693527     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25810     Document Type: Article

References (13)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
2. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513. (Pubitemid 29368252)
3. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14:2763-2767.
4. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563. (Pubitemid 47106144)
5. Rosenberg JE, Ryan CJ, Weinberg VK, et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009;27:2772-2778.
6. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17:3461-3467. (Pubitemid 29517916)
7. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
8. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Paper presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California.
9. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005; 23:2726-2734. (Pubitemid 46179462)
10. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399-3406. (Pubitemid 47310875)
11. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414. (Pubitemid 47310876)
12. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as firstline therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415-3420. (Pubitemid 47310877)
13. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007;25:3421-3427. (Pubitemid 47310878)